Gly­coMimet­ic­s' AML drug flunks Phase 3 tri­al, quash­ing fil­ing plans as stock sinks

Gly­coMimet­ics’ stock $GLYC tanked over 60% in pre­mar­ket trad­ing Mon­day morn­ing af­ter the biotech an­nounced a Phase 3 tri­al fail­ure for its lead drug, up­ro­le­se­lan, in re­lapsed/re­frac­to­ry acute myeloid leukemia.

In the 388-pa­tient tri­al, those treat­ed with up­ro­le­se­lan and chemother­a­py had a me­di­an over­all sur­vival of 13 months com­pared to 12.3 months for those on a place­bo and chemother­a­py, mean­ing the com­pa­ny’s drug com­bo did not achieve a sta­tis­ti­cal­ly sig­nif­i­cant im­prove­ment in the pri­ma­ry end­point of over­all sur­vival in the in­tent-to-treat pop­u­la­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER